Melissa Abel
Public Communications Contact chez 89BIO, INC.
Profil
Melissa Abel is currently working as the VP-Commercial Strategy & Communications at 89bio, Inc. Previously, she held the position of Vice President-Commercial Strategy at Five Prime Therapeutics, Inc. from 2016 to 2020, and at Concentric Analgesics, Inc. from 2016 to 2020.
Prior to that, Melissa worked at Smithkline Beecham from 1995 to 1999 in Sales & Marketing.
Melissa holds an MBA from Emory University and an undergraduate degree from The University of Chicago.
Postes actifs de Melissa Abel
| Sociétés | Poste | Début |
|---|---|---|
| 89BIO, INC. | Public Communications Contact | - |
Anciens postes connus de Melissa Abel
| Sociétés | Poste | Fin |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2020 |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/01/2020 |
| Smithkline Beecham | Sales & Marketing | 02/01/1999 |
Formation de Melissa Abel
| Emory University | Masters Business Admin |
| The University of Chicago | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 89BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Smithkline Beecham | |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Technology Services |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
